drugset
drugset / Trial / NCT03596632

Study Investigating a Single Oral Dose of Fenebrutinib in Healthy Volunteers

NCT03596632 ↗

Phase 1 Completed 8 enrolled Hoffmann-La Roche
NaSingle-groupOpen-labelDiagnostic

Summary

The purpose of this study is to determine the excretion kinetics and mass balance of fenebrutinib in healthy male subjects.

Timeline

Start
2018-07-27
Primary completion
2018-08-23
Completion
2018-08-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Fenebrutinib Small molecule 200 mg Oral

Indications

No indication recorded.